Obesity Capsule Maker Wants $60M IPO After $22M Financing
The Boston-based biotech company has not yet decided how many shares it will offer or a price for the offering. The private financing came in exchange for convertible preferred stock.
Both sources of income will be used to help the company develop its weight-loss therapy, which is currently in clinical trials.
“We're pleased to receive this...
To view the full article, register now.